BioSpace News Archive

Deals

Moderna to Present at Upcoming Investor Conferences in March

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences:

March 4, 2019
·
2 min read
Deals

AGC Completes Acquisition of Spanish Synthetic Pharmaceutical Active Ingredient Manufacturer Malgrat Pharma Chemicals

AGC Inc. based in Tokyo announced on March 4 the completion of its acquisition of Spain’s synthetic pharmaceutical active ingredient manufacturer, Malgrat Pharma Chemicals, S.L.U..

March 4, 2019
·
2 min read
NEX China Takes the Express for Healthy Food Together with Natural Extract Enterprises

In recent years, big health has risen as a national policy of China with the introduction of the “Healthy China 2030" Planning Outline, and China has specified the new positioning of the nutrition and health food industry.

March 4, 2019
·
5 min read
Immunovia Provides an Update on the Optimization Work to Meet the Expected Performance for Commercialization of IMMray™ PanCan-d

Immunovia has secured blood samples that best conforms to real-life, commercial conditions, which will form the basis for the commercial test model study.

March 4, 2019
·
4 min read
Masimo Announces CE Marking of Pediatric Indication for Next Generation SedLine® Brain Function Monitoring

Next Generation SedLine Now Available for Use on Patients 1-18 Years Old in CE Mark Countries

March 4, 2019
·
7 min read
Policy

Arcadia Biosciences Receives Its First Industrial Hemp Program License in Hawaii

The company’s new cannabis-dedicated operating unit, Arcadia Specialty Genomics, will commence research this April with a new 10-acre hemp cultivation facility.

March 4, 2019
·
5 min read
Bio NC

United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference

United Therapeutics Corporation announced that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company’s business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.

March 4, 2019
·
1 min read
Drug Development

BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

Company anticipates announcing topline efficacy and safety results in July 2019

March 4, 2019
·
3 min read
Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting

Retrospective study analyzed the relationship between continued systemic treatment and various healthcare resources and costs such as ER costs, ER visits, hospitalizations, and total inpatient days

March 4, 2019
·
5 min read
Policy

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of a new extended dosing schedule for KEYTRUDA®, Merck’s anti-PD-1 therapy, for all approved monotherapy indications in the European Union.

March 4, 2019
·
27 min read